Phase 4 N=15 Hepatitis C Virus(HCV) Heart and Lung Study
Hepatitis C, Chronic · Heart Failure · Pulmonary Disease, Chronic Obstructive
Primary: Number of Subjects Who Completed 24 Weeks of Therapy — 0; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=25 HCV Positive Heart Donors
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
Phase 1 N=20 Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.
Hepatitis, Chronic · Hepatitis C Virus
Primary: Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 11 (Cohort A): Full Analysis Set — 6.11; -0.45 log10 IU/mL
Phase 4 N=21 Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
Phase 4 N=87 Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
Cardiovascular Diseases · Hepatitis C · Hiv
Primary: Change in Cardiovascular Disease Risk From Baseline to After Functional Cure of Hepatitis C, as Measured by High-sensitivity C-reactive Protein — 0.6; 0 mg/L
N/A N=2,209 Hepatitis C Testing in VA Community-Based Outpatient Clinics
Hepatitis C
Primary: HCV Antibody Test — 574 Participants
N/A N=309 Hepatitis C Translating Initiatives for Depression Into Effective Solutions
Hepatitis C · Depression
Primary: Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment — 11; 7 participants
Phase 4 N=122 Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
Hepatitis C · Transplantation Disease Transmission
Primary: Proportion of Participants With HCV RNA Level Below Limits of Quantification (LOQ) — 23 Participants
Phase 1 N=5 Viral Kinetics in HCV Clearance in Subjects With Hemophilia
Chronic Hepatitis C · Hemophilia
Primary: Number of Participants With Sustained Virological Response at Week 12 (SVR12) — 2; 2 participants
Phase 2 N=548 Staged Phase I/II Hepatitis C Prophylactic Vaccine
Hepatitis C
Primary: Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months — 14; 14 Participants — p=0.317
N/A N=366 Undiagnosed Hepatitis C Infection in an Urban Hospital
Hepatitis C
Primary: Point Prevalence of Hepatitis C Infection — 9 percentage of total subjects
N/A N=68 Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection
HIV · Hepatitis C, Chronic
Primary: Number of Participants Linked to Care — 8; 16 Participants — p=0.036
N/A N=176 Hepatitis C-Video vs. Brochure Education Delivery
Hepatitis C
Primary: Improvement in Scores on HCV Knowledge Questionnaire — 18.45; 19; 20.3; 21.75 Improvement in scores
Phase 2 N=128 A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study
Hepatitis C
Primary: Comparison of Sustained Viral Response at 12 Weeks Post Treatment (SVR12) in the Three Treatment Groups. — 3; 5; 3; 30 Participants — p=0.67
N/A N=795 Association of Hepatitis C Virus With Breast Cancer
Breast Cancer · Hepatitis C
Primary: Prevalence of HCV Seropositivity in Breast Cancer Patients. — 88; 15; 317; 130 Participants — p=0.0027
Phase 2 N=15 Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
Hepatitis C
Primary: Intrahepatic and Plasma HCV Viral Kinetics — 6.5; 4.9; 3.2; 4.2 log transformed copies/ml
N/A N=134 Hepatitis C Self-Management
Hepatitis C · Chronic Disease
Primary: Quality of Well-being Scale - Self-Administered (QWB-SA) — .534; .501; .600; .504 units on a scale
N/A N=21 Hepatitis C Virus (HCV) Treatment Completion or Withdrawal
Hepatitis C
Primary: Attributes of Treatment Experience — 14; 15; 7; 9 participants
Phase 4 N=18 HCV-HIV Co-infected Patient Cohort in Thailand
Hepatitis C Infection · HIV
Primary: Number of Participants With Sustained Virological Response 6 Months After Treatment Discontinuation — 10 Participants
Phase 2 N=32 A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
Chronic Hepatitis C
Primary: Adverse Event Profile of Repeated Dosing of CF102 — 6; 2; 2; 4 participants
Phase 2 N=10 Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection
Hepatitis C, Chronic · Liver Diseases · Hepatitis
Primary: Number of Participants With Severe Adverse Reactions and/or With Abnormal Clinical Laboratory Values That Are Related to Treatment — 0 Participants
Phase 2 N=30 Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
HIV-HCV
Primary: The Percentage of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 90; 80 Percentage of subjects
Phase 4 N=30 Multi-center Study to Transplant Hepatitis-C Infected Kidneys
Renal Failure Chronic · Hepatitis C
Primary: Number of Participants With Undetectable HCV — 30 Participants
Phase 3 N=741 Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.0; 0 percentage of participants — p=< 0.001
Phase 4 N=180 Baclofen to Reduce Alcohol Use in Veterans With HCV
Hepatitis C · Alcohol Use Disorders
Primary: Number of Drinking Days in the Past Two Weeks — 8.6; 8.9; 6.8; 7.1 Number of Drinking Days/2 weeks — p=<0.01
N/A N=32 Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients
Chronic Hepatitis C
Primary: Percentage of Patients Consented Versus Approached — 74 percentage of participants
Phase 2 N=273 Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection
Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 92.9; 96.2; 74.1; 100.0 percentage of participants
Phase 2 N=57 Dutch Acute HCV in HIV Study (DAHHS)
Hepatitis C · Human Immunodeficiency Virus
Primary: Sustained Viral Response(SVR) 12 Weeks of Follow up After the End of All Therapy for the Rapid Viral Response at Week 4(RVR4) Population. — 41 participants
Phase 2 N=67 Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
HIV Infection · Hepatitis C Infection
Primary: Percentage of Participants With Complete Early Virologic Response (cEVR) — 38.8 percentage of participants
N/A N=10 Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults
Hepatitis C Virus (HCV) Infection
Primary: Number of Participants Completing HCV Treatment — 3; 6 Participants